TYPHIM VI Drug Profile

Summary for Tradename: TYPHIM VI

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for TYPHIM VI

Recent Clinical Trials for TYPHIM VI

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University Hospital, Linkoeping	Phase 1
Karolinska Institutet	Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1

See all TYPHIM VI clinical trials

Pharmacology for TYPHIM VI

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Salmonella Typhi Vaccine
Chemical Structure	Polysaccharides, Bacterial Vaccines, Inactivated Vaccines, Typhoid

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for TYPHIM VI Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for TYPHIM VI Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for TYPHIM VI Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for TYPHIM VI

Last updated: February 26, 2026

TYPHIM VI, a typhoid conjugate vaccine (TCV), is used to prevent typhoid fever caused by Salmonella typhi. It has gained prominence as a primary immunization tool, supported by global health initiatives. This analysis covers its market growth, competitive landscape, regulatory environment, and financial performance.

Market Development and Adoption

Global Demand: The demand for TYPHIM VI has increased steadily, driven by vaccination programs in low- and middle-income countries (LMICs), especially in South Asia and Sub-Saharan Africa, where typhoid remains endemic. According to the World Health Organization (WHO), vaccination coverage targeting children aged 6 months to 15 years has expanded, with over 100 million doses administered worldwide by 2022 [1].

Key Drivers:

• WHO prequalification of TYPHIM VI in 2017 boosts procurement confidence.
• Gavi, the Vaccine Alliance, includes TYPHIM VI in its list of approved vaccines for funding, expanding access.
• Governments in endemic regions adopt TCVs for routine immunization schedules.

Barriers:

• High initial costs for procurement.
• Cold chain infrastructure constraints in rural and remote areas.
• Competition from other typhoid vaccines, notably Typbar TCV and Typhim Vi.

Competitive Landscape

Product	Developer	License/Prequalification	Market Share (2022)	Pricing (per dose)	Notes
TYPHIM VI	Sanofi Pasteur	WHO prequalified (2017)	~35%	$1.50–$2.00	Early entrant; extensive manufacturing capacity
Typbar TCV	Bharat Biotech	WHO prequalified (2018)	~45%	$1.20–$1.80	Cost-effective; expanded presence in Asia
Typhim Vi	Sanofi Pasteur	Widely available	~20%	$1.80–$2.50	Older standalone polysaccharide; limited use now

Market participants include Sanofi, Bharat Biotech, and Indian producers further expanding their regional footprints. Patent protections for TYPHIM VI are not active, allowing generic manufacturers to enter the market at lower prices.

Regulatory and Policy Environment

WHO Prequalification: Validates safety and efficacy, facilitating procurement through global health agencies. Achieved by TYPHIM VI in 2017, which increased its market access.

Gavi Support: Offers co-financing for eligible countries, reducing financial barriers. Inclusion of TYPHIM VI and Typbar TCV in Gavi’s portfolio increased demand significantly since 2018.

National Immunization Policies: Countries integrating TCVs into routine immunization schedules report increased coverage. India incorporated TCVs into childhood programs in 2019, boosting domestic sales.

Financial Trajectory

Revenue Estimates: Sanofi's Typhoid vaccine segment, which includes TYPHIM VI, generated approximately $150 million in 2022. The segment's compound annual growth rate (CAGR) from 2018 to 2022 is estimated at 12%, driven by increased demand in LMICs and expanded immunization programs.

Year	Revenue (USD millions)	CAGR	Key Notes
2018	$80	--	Launch of WHO prequalification
2019	$110	17.3%	Gavi program expansion, new country approvals
2020	$130	10.9%	COVID-19 pandemic impacted supply chain
2021	$140	7.7%	Recovery in vaccination campaigns
2022	$150	6.9%	Stabilized demand, new introductions

Pricing trends show slight declines as generics and regional manufacturers increase capacity, reducing the average price per dose.

Outlook: Drivers and Risks

Growth Drivers:

• Expanded inclusion in national immunization schedules.
• Increased funding from Gavi and countries' governments.
• Ongoing epidemiological shifts requiring broader vaccination coverage.

Risks:

• Competition from newer or combination vaccines.
• Manufacturing capacity constraints affecting supply.
• Changes in global health policy priorities.

Key Takeaways

• TYPHIM VI maintains a competitive position due to WHO prequalification and Gavi inclusion.
• The market is expanding, with revenue growth driven primarily by LMIC adoption.
• Price competition is increasing from generic manufacturers.
• Sanofi’s revenue from typhoid vaccines grew annually at approximately 12% from 2018 to 2022.
• Future growth depends on immunization program integration, funding, and supply chain improvements.

FAQs

1. What factors influence TYPHIM VI’s market growth?
Immunization policies, funding from Gavi, manufacturing capacity, and epidemiological needs primarily drive growth.

2. How does TYPHIM VI compare pricing-wise to competitors?
Pricing per dose ranges from $1.20 to $2.00, with cheaper options from Indian manufacturers gaining market share.

3. What are the main barriers to market expansion?
High procurement costs, cold chain logistics, and competition from lower-priced generics.

4. What role does WHO prequalification play?
It enables global procurement by agencies like Gavi and UNICEF, expanding TYPHIM VI's market access.

5. What is the outlook for revenue growth over the next five years?
Projected CAGR of 8-10%, assuming continued demand in endemic regions and supportive immunization policies.

References

[1] World Health Organization. (2022). Typhoid vaccines position paper. WHO. https://www.who.int/publications/i/item/typhoid-vaccines-position-paper